Background Sofosbuvir is a nucleoside analogue inhibitor of the HCV NS5B polymerase
approved for treatment of HCV-infected patients in combination with ribavirin or with other …

Background: The HCV NS5B S282T mutation was selected by sofosbuvir (SOF, formerly GS-
7977) in genotype 1a, 1b, and 2a replicon cells in vitro. Given the pan-genotypic coverage of …

High sequence diversity of HCV may lead to variation in susceptibility to antiviral agents
amongst different genotypes and subtypes of the virus. We assessed the susceptibility to …

Background The prevalence of natural polymorphisms associated with resistance to NS5B
nucleoside/nucleotide (NI) sofosbuvir is distinct in different geographical regions. In Brazil …

Hepatitis C virus (HCV) infection remains a challenge to human public health despite the
development of highly effective direct‐acting antivirals (DAAs). Sofosbuvir (SOF), a key …

Clinical phase II/III studies of the nucleotide analogue HCV NS 5B inhibitor sofosbuvir (SOF)
have demonstrated high efficacy in HCV‐infected patients in combination therapy. To date …

Background & Aims Sofosbuvir is a frequently used pan-genotype inhibitor of hepatitis C
virus (HCV) polymerase. This drug eliminates most chronic HCV infections, and resistance …

Introduction: Sofosbuvir (SOF, formerly GS-7977), a novel HCV NS5B nucleotide inhibitor,
demonstrated potent antiviral activity with broad HCV genotype coverage with excellent high …

Background The major resistance-associated substitution for sofosbuvir (S282T) in HCV
NS5B causes severe viral fitness costs and rapidly reverts back to prototype in the absence …

Background & Aims The fixed-dose combination of sofosbuvir/velpatasvir was highly
efficacious in patients infected with genotype (GT) 1–6 hepatitis C virus (HCV) in the …